EORTC-GU group expert opinion on metastatic renal cell cancer
- 31 March 2009
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (5), 765-773
- https://doi.org/10.1016/j.ejca.2008.12.010
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell CarcinomaJournal of Urology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsBritish Journal of Cancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agentsBJU International, 2006
- To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasoundEuropean Journal Of Cancer, 2006
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACEJournal of Urology, 1999